News

Dr. Gareth Lavery, a prominent researcher with the University of Birmingham’s Centre for Endocrinology, Diabetes and Metabolism (CEDAM), has been awarded a prestigious Senior Fellowship in Basic Biomedical

The patent (EP 2219451 B1) is drawn to the use of OXi4503 in treating non-solid myeloid neoplasm, including acute myeloid leukemia (AML). "We are pleased to be granted

Teva’s Celecoxib is also indicated for the short-term management of moderate to severe acute pain in adults, in conditions such as musculoskeletal and/or soft tissue trauma including sprains,

Keryx is a biopharmaceutical firm focused on bringing new therapies to market for patients with renal disease. In September 2014, Auryxia was approved by the FDA to control

Under the deal, Allergan investors would receive $129.22 in cash and 0.3683 Actavis shares for each share of the Botox-maker’s common stock. The combination will create one of

Both the firms will explore the therapeutic potential of this new anti-PD-L1 antibody as a single agent as well as in various combinations with their broad portfolio of

As part of this deal, all of Roche’s rights to INO-5150, including the right to license the product to other parties, will be returned to Inovio, which now

The project will focus on non-valvular atrial fibrillation (NVAF) and will examine disease prevalence, treatment complications, such as hospital readmissions, as well as the use of evidence-based guidelines.

The randomized double blind trial included a total of 418 patients with treatment naïve BRAF wild-type unresectable Stage III and IV melanoma and they were given either Opdivo